MAP2K7 and colorectal carcinoma: The ANCHOR CRC single-arm, phase II study (43) in first-line BRAFV600E mCRC patients, recently published at World Congress on GI Cancer 2020, aimed to investigate the efficacy of triplet therapy with BRAF inhibitor encorafenib, MEK inhibitor binimetinib, combined with cetuximab in treatment-naïve patients with RAS WT/BRAF V600E mutant mCRC, in which 51% of the patients had peritoneal metastases.